241 related articles for article (PubMed ID: 38784980)
21. Tubulin inhibitors as novel anticancer agents: an overview on patents (2013-2018).
Haider K; Rahaman S; Yar MS; Kamal A
Expert Opin Ther Pat; 2019 Aug; 29(8):623-641. PubMed ID: 31353978
[No Abstract] [Full Text] [Related]
22. Checkpoint kinase inhibitors: a review of the patent literature.
Janetka JW; Ashwell S
Expert Opin Ther Pat; 2009 Feb; 19(2):165-97. PubMed ID: 19441917
[TBL] [Abstract][Full Text] [Related]
23. A patent review of cyclin-dependent kinase 7 (CDK7) inhibitors (2018-2022).
Kovalová M; Baraka JP; Mik V; Jorda R; Luo L; Shao H; Kryštof V
Expert Opin Ther Pat; 2023 Feb; 33(2):67-87. PubMed ID: 36975020
[TBL] [Abstract][Full Text] [Related]
24. Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.
Kettle JG; Åstrand A; Catley M; Grimster NP; Nilsson M; Su Q; Woessner R
Expert Opin Ther Pat; 2017 Feb; 27(2):127-143. PubMed ID: 27774824
[TBL] [Abstract][Full Text] [Related]
25. Ribosomal S6 kinase (RSK) modulators: a patent review.
Ludwik KA; Lannigan DA
Expert Opin Ther Pat; 2016 Sep; 26(9):1061-78. PubMed ID: 27410995
[TBL] [Abstract][Full Text] [Related]
26. Checkpoint kinase inhibitors: a patent review (2009 - 2010).
Lainchbury M; Collins I
Expert Opin Ther Pat; 2011 Aug; 21(8):1191-210. PubMed ID: 21599421
[TBL] [Abstract][Full Text] [Related]
27. c-Met kinase inhibitors: an update patent review (2014-2017).
Zhang QW; Ye ZD; Shi L
Expert Opin Ther Pat; 2019 Jan; 29(1):25-41. PubMed ID: 30474428
[TBL] [Abstract][Full Text] [Related]
28. PDK1 inhibitors.
Barile E; De SK; Pellecchia M
Pharm Pat Anal; 2012 May; 1(2):145-63. PubMed ID: 24236780
[TBL] [Abstract][Full Text] [Related]
29. Interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitors: an updated patent review (2016-2018).
McElroy WT
Expert Opin Ther Pat; 2019 Apr; 29(4):243-259. PubMed ID: 30916602
[TBL] [Abstract][Full Text] [Related]
30. Aurora kinase inhibitor patents and agents in clinical testing: an update (2011 - 2013).
Cheung CH; Sarvagalla S; Lee JY; Huang YC; Coumar MS
Expert Opin Ther Pat; 2014 Sep; 24(9):1021-38. PubMed ID: 24965505
[TBL] [Abstract][Full Text] [Related]
31. Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part I.
Bailey JJ; Schirrmacher R; Farrell K; Bernard-Gauthier V
Expert Opin Ther Pat; 2017 Jun; 27(6):733-751. PubMed ID: 28270010
[TBL] [Abstract][Full Text] [Related]
32. AMP-activated protein kinase modulators: a patent review (2006 - 2010).
Yun H; Ha J
Expert Opin Ther Pat; 2011 Jul; 21(7):983-1005. PubMed ID: 21548715
[TBL] [Abstract][Full Text] [Related]
33. Rho kinase inhibitors: a patent review (2014 - 2016).
Defert O; Boland S
Expert Opin Ther Pat; 2017 Apr; 27(4):507-515. PubMed ID: 28048944
[TBL] [Abstract][Full Text] [Related]
34. Trk kinase inhibitors as new treatments for cancer and pain.
Wang T; Yu D; Lamb ML
Expert Opin Ther Pat; 2009 Mar; 19(3):305-19. PubMed ID: 19441906
[TBL] [Abstract][Full Text] [Related]
35. Cyclin-dependent kinase 4/6 inhibitors for cancer therapy: a patent review (2015 - 2019).
Wang PF; Qiu HY; He Y; Zhu HL
Expert Opin Ther Pat; 2020 Oct; 30(10):795-805. PubMed ID: 32945222
[TBL] [Abstract][Full Text] [Related]
36. A patent review of RAF kinase inhibitors (2010-2018).
Man RJ; Zhang YL; Jiang AQ; Zhu HL
Expert Opin Ther Pat; 2019 Sep; 29(9):675-688. PubMed ID: 31370713
[No Abstract] [Full Text] [Related]
37. Sirtuin modulators: where are we now? A review of patents from 2015 to 2019.
Mautone N; Zwergel C; Mai A; Rotili D
Expert Opin Ther Pat; 2020 Jun; 30(6):389-407. PubMed ID: 32228181
[TBL] [Abstract][Full Text] [Related]
38. Successes and challenges in the development of BD1-selective BET inhibitors: a patent review.
Viviano M; Cipriano A; Fabbrizi E; Feoli A; Castellano S; Sbardella G; Mai A; Milite C; Rotili D
Expert Opin Ther Pat; 2024 Jul; 34(7):529-545. PubMed ID: 38465537
[TBL] [Abstract][Full Text] [Related]
39. Quinazoline derivatives as anticancer drugs: a patent review (2011 - present).
Ravez S; Castillo-Aguilera O; Depreux P; Goossens L
Expert Opin Ther Pat; 2015 Jul; 25(7):789-804. PubMed ID: 25910402
[TBL] [Abstract][Full Text] [Related]
40. Drug discovery targeting p21-activated kinase 4 (PAK4): a patent review.
Wang H; Song P; Gao Y; Shen L; Xu H; Wang J; Cheng M
Expert Opin Ther Pat; 2021 Nov; 31(11):977-987. PubMed ID: 34369844
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
